CJC-1295 / Ipamorelin Peptide Screening Form Template

CJC-1295 and Ipamorelin are growth hormone-releasing peptides (GHRPs) that stimulate the pituitary gland to produce more growth hormone. They are prescribed off-label for body composition, recovery, sleep quality, and anti-aging indications. This screening form helps providers identify appropriate candidates while documenting contraindications including metabolic conditions, pituitary disorders, and hormone-sensitive conditions prior to initiating a growth hormone secretagogue protocol.

4 sections
17 fields
HIPAA-ready
3 citations

Free Template

CJC-1295 / Ipamorelin Peptide Screening Form

Preview Form Automate This Form
No account required to use template
Customize with your practice branding
Reviewed against HIPAA & DEA guidelines

Form Preview

This is how the form appears to patients. Customize with your practice name and branding.

Your Practice Name

CJC-1295 / Ipamorelin Peptide Screening Form

Preview
1

General Patient Information

Please provide your personal information.

First Name

Jane

Last Name

Smith

Date of Birth

Can you confirm you are 18 years or older?

Height

e.g. 5'8"

Weight

e.g. 170 lbs

2

Medical History

Please answer all questions as accurately as possible. Your provider will review this information.

Are you actively taking any medications? If so, please list them.

List all current medications, dosages, and frequencies

Do you have any medication allergies? If so, please list them.

List all known drug allergies and reactions

Are you currently being treated or have you been treated for any medical conditions? If so, please list them.

List all current and past medical conditions

Have you had any past surgeries? If so, please list them.

List all surgeries and approximate dates

What is/was your sex assigned at birth?

Male

Emergency contact name and phone number

Name — (555) 000-0000

Mailing address

123 Main St, City, State, ZIP

Any other questions or concerns?

Optional — share anything else you'd like your provider to know

3

Symptoms

Select all symptoms that currently apply to you.

Which of the following symptoms are you experiencing?
4

Medical Conditions

Select all conditions that currently apply to you.

Do any of the following apply to you?

Preview only. Your live form will include your branding and e-signature capture.

Submit

Compliance & Regulatory Notes

Review these notes before deploying this form in your practice.

CJC-1295 and Ipamorelin are growth hormone secretagogues prescribed off-label. Informed consent documenting the off-label nature is required. See FSMB: https://www.fsmb.org

Growth hormone secretagogues may affect insulin sensitivity and blood glucose. Patients with diabetes or metabolic disorders require closer monitoring.

These peptides must be dispensed by a licensed compounding pharmacy. Verify 503A/503B status. See FDA: https://www.fda.gov/drugs/human-drug-compounding

Want This Form Automated?

Karpa Health turns static intake forms into a fully automated clinical workflow. Branded, HIPAA-compliant, and connected to compounding pharmacies.

  • Branded intake on your website
  • AI contraindication screening
  • One-click prescribing to pharmacies
  • Automated refill management
  • E-signatures and HIPAA audit trail
  • 50-state provider network included
Book a Demo

Free 30-minute walkthrough

Sources & References

  1. FDA Human Drug Compounding Guidance
  2. FSMB Off-Label Prescribing Guidelines
  3. Endocrine Society Clinical Practice Guidelines

Frequently Asked Questions

What is the difference between CJC-1295 and Ipamorelin?

CJC-1295 is a GHRH analog that stimulates sustained growth hormone release, while Ipamorelin is a GHRP that mimics ghrelin to trigger pulsatile GH release. They are often combined for synergistic effect on growth hormone secretion.

Why is diabetes a contraindication for growth hormone secretagogues?

Growth hormone can increase insulin resistance and elevate blood glucose. Patients with diabetes or impaired glucose tolerance require careful monitoring and may not be appropriate candidates without additional evaluation.